Ranjan Redoy, Hasan Md Kamrul, Adhikary Asit Baran
Department of Cardiac Surgery, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh.
Department of Cardiac Surgery, National Institute of Cardiovascular Diseases, Dhaka, Bangladesh.
Int J Gen Med. 2024 May 28;17:2507-2512. doi: 10.2147/IJGM.S466706. eCollection 2024.
Genetic factors contribute significantly to the risk of ischaemic heart disease (IHD), which is the leading cause of mortality in Bangladesh. The BANGABANDHU (Bangladeshi Atherosclerosis Biobank AND Hub) study will allow a hypothesis-free genome-wide association study (GWAS) to identify genetic risk factors associated with ischaemic heart disease patients undergoing coronary artery bypass graft (CABG) surgery in Bangladesh.
This is a multi-centre population-based case-control study aimed to evaluate 1500 (Fifteen Hundred) adult (≥18 years of age) people divided into 2 study groups: Case/Proband (750 IHD patients undergoing CABG surgery) and Control (750 healthy people). Spouses or family members are preferred as healthy control subjects due to their shared geographic location and similar environmental exposure.
This will be the first largest DNA repository of CABG patients in Bangladesh, and identifying novel gene loci among CABG patients might help to discover novel therapeutic targets for Bangladeshi IHD patients. Further, identifying and comparing novel gene loci among CABG patients with other ancestry might help devise national guidelines for treating coronary artery disease.
Promising current study results will encourage Bangladeshi researchers and pharmaceutical companies to conduct further studies into the genetic basis of Bangladeshi complex coronary artery disease, which might identify novel genes for therapeutic targets for Bangladeshi patients and strengthen the healthcare standards in Bangladesh.
遗传因素在缺血性心脏病(IHD)风险中起重要作用,缺血性心脏病是孟加拉国的主要死因。孟加拉国动脉粥样硬化生物样本库与研究中心(BANGABANDHU)研究将开展一项无假设的全基因组关联研究(GWAS),以识别与孟加拉国接受冠状动脉搭桥术(CABG)的缺血性心脏病患者相关的遗传风险因素。
这是一项基于人群的多中心病例对照研究,旨在评估1500名(一千五百名)成年人(≥18岁),分为2个研究组:病例/先证者组(750名接受CABG手术的IHD患者)和对照组(750名健康人)。由于地理位置相同和环境暴露相似,配偶或家庭成员优先作为健康对照受试者。
这将是孟加拉国最大的CABG患者DNA储存库,在CABG患者中识别新的基因位点可能有助于发现孟加拉国IHD患者的新治疗靶点。此外,在不同血统的CABG患者中识别和比较新的基因位点可能有助于制定治疗冠状动脉疾病的国家指南。
目前有前景的研究结果将鼓励孟加拉国的研究人员和制药公司对孟加拉国复杂冠状动脉疾病的遗传基础进行进一步研究,这可能会识别出孟加拉国患者治疗靶点的新基因,并提高孟加拉国的医疗保健标准。